Germany – Services provided by medical laboratories – Immunhistologie Studie ToMA4TA1

Charité - Universitätsmedizin Berlin is tendering a framework agreement for highly specialized immunohistochemical (IHC) laboratory services to detect tumor antigen MAGE-A4 in human FFPE tumor tissue for the clinical study 'ToMA4TA1'. The tender is restricted to German-language electronic submissions, with a deadline of 18 June 2026. The estimated value is not disclosed. The award is based 50% on price and 50% on quality (Umsetzungskonzept). Strict eligibility criteria include at least 3 comparable references, CAP/CLIA accreditation, ISO 15189 certification, access to a biobank with ≥10,000 FFPE blocks, and on-site capability for IHC and RT-PCR.